{"id":8863,"date":"2021-04-08T11:21:56","date_gmt":"2021-04-08T18:21:56","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8863"},"modified":"2021-04-13T10:52:22","modified_gmt":"2021-04-13T17:52:22","slug":"cross-reactive-neutralizing-antibody-responses-elicited-by-sars-cov-2-501y-v2-b-1-351","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/08\/cross-reactive-neutralizing-antibody-responses-elicited-by-sars-cov-2-501y-v2-b-1-351\/","title":{"rendered":"Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Antibody responses to the B.1.351 SARS-CoV-2 variant (aka, 501Y.V2) in a cohort of patients hospitalized with COVID-19 in South Africa (n=89) were found to be robust and <\/span><span style=\"font-weight: 400\">showed high levels of cross-reactivity against the virus strain from the first wave. Furthermore, sera from patients infected with <\/span><span style=\"font-weight: 400\">B.1.351 <\/span><span style=\"font-weight: 400\">also neutralized the P.1 variant (aka, 501Y.V3) first described in Brazil, suggesting that the antibody response in patients infected with <\/span><span style=\"font-weight: 400\">the B.1.351 variant has high levels of cross-reactivity across variants. The authors suggest that these results indicate that vaccines built on the spike protein of B.1.351 may be promising candidates for elicitating cross-reactive neutralizing antibody responses to SARS-CoV-2. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: A pre-print version of this article was summarized in this report on March 10, 2021].<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Moyo-Gwete et al. (Apr 7, 2021). Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine.<\/span><\/i> <a href=\"https:\/\/doi.org\/10.1056\/NEJMc2104192\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1056\/NEJMc2104192<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibody responses to the B.1.351 SARS-CoV-2 variant (aka, 501Y.V2) in a cohort of patients hospitalized with COVID-19 in South Africa (n=89) were found to be robust and showed high levels of cross-reactivity against the virus strain from the first wave. Furthermore, sera from patients infected with B.1.351 also neutralized the P.1 variant (aka, 501Y.V3) first&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/08\/cross-reactive-neutralizing-antibody-responses-elicited-by-sars-cov-2-501y-v2-b-1-351\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[159],"topic":[31],"class_list":["post-8863","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8863"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8863\/revisions"}],"predecessor-version":[{"id":8864,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8863\/revisions\/8864"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8863"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}